Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc 99m Tilmanocept Imaging in Rheumatoid Arthritis
NCT03938636Phase 2Completed
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Apr 2019
- Primary completion
- Feb 2021
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
Phase 2, open-label trial of technetium tc 99m tilmanocept in rheumatoid arthritis (RA) (3 arms), sponsored by Navidea Biopharmaceuticals, Inc. Primary endpoints: Camera-specific Precision of Tilmanocept Uptake Value at Day 0, Stability of the Mean/Variance Relationship of TUV at Day 0 and 2 more. Started Apr 2019; status: completed.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03938636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03938636.